Apellis Pharmaceuticals, Inc. (FRA:1JK)
Germany flag Germany · Delayed Price · Currency is EUR
18.50
-0.04 (-0.21%)
At close: Jan 30, 2026

Apellis Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
44.99-197.88-528.63-652.17-746.35-344.87
Depreciation & Amortization
1.681.81.781.551.490.86
Other Amortization
2.431.560.30.460.9615.54
Loss (Gain) From Sale of Assets
--0.12---
Stock-Based Compensation
109.07114.13105.9591.0970.6745.38
Other Operating Activities
-10.892661.09203.63103.03
Change in Accounts Receivable
-66.52-58.48-198.722.38-10.1-
Change in Inventory
3.41-10.76-60.65-69.4-16.32-
Change in Accounts Payable
1.521.090.1718.6910.49-0.05
Change in Other Net Operating Assets
-15.8149.7958.9432.57-77.5919.64
Operating Cash Flow
78.86-87.87-594.74-513.75-563.13-160.49
Capital Expenditures
-0.23-0.4-0.77-1.52-1.1-5.42
Sale of Property, Plant & Equipment
--0.1---
Investment in Securities
---61.42248.72-311.57
Investing Cash Flow
-0.23-0.4-0.6759.89247.62-316.99
Long-Term Debt Issued
-365.45---322.87
Net Debt Issued (Repaid)
-365.45---322.87
Issuance of Common Stock
9.2818.83461.04405.84398.02392.42
Repurchase of Common Stock
-0.03-0.06-11.04-5.68-1.79-
Other Financing Activities
-5.63-234.98-55.5-34.5-4-23.11
Financing Cash Flow
3.63149.24394.5365.66392.24692.18
Foreign Exchange Rate Adjustments
0.1-0.660.14-0.49-2.020.36
Net Cash Flow
82.3660.31-200.78-88.6874.71215.06
Free Cash Flow
78.64-88.27-595.51-515.27-564.23-165.91
Free Cash Flow Margin
7.74%-11.30%-150.16%-683.18%-847.66%-66.19%
Free Cash Flow Per Share
0.61-0.71-5.02-4.86-6.68-2.21
Cash Interest Paid
41.8129.373.29510.2712.93
Cash Income Tax Paid
1.91.65-1.764.920.051.65
Levered Free Cash Flow
49.29-35.7-404.84-304.6-351.61-52.88
Unlevered Free Cash Flow
75-12.01-386.65-284.66-344.3-49.7
Change in Working Capital
-79.3-18.36-200.25-15.76-93.5219.59
Source: S&P Global Market Intelligence. Standard template. Financial Sources.